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In Brief
Kruziki et al. present a small protein
scaffold (Gp2) that enables simple de
novo ligand discovery and evolution
toward multiple targets. Gp2 uniquely
combines robust evolution, small size (45
amino acids), nanomolar affinity, and high
thermal stability.
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Small protein ligands can provide superior physio-
logical distribution compared with antibodies, and
improved stability, production, and specific conjuga-
tion. Systematic evaluation of the PDB identified a
scaffold to push the limits of small size and robust
evolution of stable, high-affinity ligands: 45-residue
T7 phage gene 2 protein (Gp2) contains an a helix
opposite a b sheet with two adjacent loops amenable
to mutation. De novo ligand discovery from 108 mu-
tants and directed evolution toward four targets
yielded target-specific binders with affinities as
strong as 200 ± 100 pM, Tms from 65
C ± 3C to
80C ± 1C, and retained activity after thermal dena-
turation. For cancer targeting, a Gp2 domain for
epidermal growth factor receptor was evolved with
18 ± 8 nM affinity, receptor-specific binding, and
high thermal stability with refolding. The efficiency
of evolving newbinding function and the size, affinity,
specificity, and stability of evolved domains render
Gp2 a uniquely effective ligand scaffold.
INTRODUCTION
Molecules that bind targets specifically and with high affinity
are useful clinically for imaging, therapeutics, and diagnostics
as well as scientifically as reagents for biological modulation,
detection, and purification. Antibodies have been successfully
used for these applications in many cases, but their drawbacks
have instigated a search for alternative protein scaffolds from
which improved binding molecules can be developed (Banta
et al., 2013; Stern et al., 2013). Biodistribution mechanisms
such as extravasation (Schmidt and Wittrup, 2009; Yuan et al.,
1995) and tissue penetration (Thurber et al., 2008a, 2008b) are
limited by large size (150 kDa for immunoglobulin G, 50 kDa for
antigen-binding fragments, and even 27 kDa for single-chain
variable fragments), thereby reducing delivery to numerous
locales including many solid tumors. In addition, large size and
FcRn-mediated recycling slow plasma clearance (Lobo et al.,
2004). While beneficial for minimally toxic molecular therapeutic
applications, slow clearance greatly hinders molecular imaging
and systemically toxic therapeutics such as radioimmunother-
apy (Wu and Senter, 2005) via high background. Smaller agents
yield improved results (Natarajan et al., 2013; Orlova et al., 2009;946 Chemistry & Biology 22, 946–956, July 23, 2015 ª2015 Elsevier LZahnd et al., 2010). Moreover, small size does not preclude
therapeutic applications where blocking a protein or protein
interaction is required (Fleetwood et al., 2014). As scientific
reagents, small size aids synthesis and selective conjugation,
including protein fusion. Yet significant reduction in scaffold
size increases the challenge of balancing evolved intermolecular
interaction demands for affinity (Chen et al., 2013; Engh and
Bossemeyer, 2002) or function while retaining beneficial intra-
molecular interactions for stability and solubility.
Protein scaffolds, frameworks upon which numerous func-
tionalities can be independently engineered, offer a consistent
source of binding reagents for the multitude of biomarkers
and applications thereof (Banta et al., 2013; Sidhu, 2012; Stern
et al., 2013). A successful protein scaffold should be efficiently
evolvable to contain all of the following properties. High affinity
(low-nanomolar dissociation constant) and specificity provide
potent delivery (Schmidt and Wittrup, 2009; Zahnd et al.,
2010), reduce side effects in clinical applications, and are requi-
site for precise use in biological study. Stable protein scaffolds
provide tolerance to mutations in the search for diverse and
improved function (Bloom et al., 2006), resistance to chemical
and thermal degradation in production and synthetic manipula-
tion, in vivo integrity to avoid immunogenicity and off-target
effects (Hermeling et al., 2004; Rosenberg, 2006), and robust-
ness to harsh washing conditions in vitro. Contrary to the
multi-domain architecture of many antibodies and fragments,
single-domain architecture facilitates production of native li-
gands as well as incorporation into protein fusions and other
multicomponent systems. Cysteine-free structure allows for
bacterial production in the reducing Escherichia coli cellular
environment, intracellular stability in mammals, and the option
of a genetically introduced thiol for site-specific chemical
conjugation.
A multitude of alternative protein scaffolds have arisen that
possess many of these beneficial properties (Table S1). Fibro-
nectins (11 kDa) (Koide et al., 1998; Lipovsek, 2011), nanobodies
(11 kDa) (Revets et al., 2005), designed ankyrin repeat proteins
(20 kDa) (Tamaskovic et al., 2012), and anticalins (20 kDa)
(Gebauer and Skerra, 2012) have been evolved to interact with
numerous targets with high affinity while maintaining stability.
However, the relatively large size of these scaffolds leaves
room for potential improvement in solid tumor penetration
and biodistribution through decreased size. Very small size has
been achieved in the case of the cystine knottin scaffold
(20–50 amino acids) (Moore et al., 2012) and cyclic peptides
(17 amino acids) (Heinis et al., 2009). Knottins often use grafting
of known binding motifs, which is only applicable to a subset
of targets (Ackerman et al., 2014), although binders have beentd All rights reserved
evolved from naive libraries (Getz et al., 2011). Peptides, partially
due to limited potential for interfacial area as well as the entropic
cost of conformational flexibility (Castel et al., 2011), often
require extensive optimization to yield the affinity and specificity
required for many applications. In addition, the multiple disulfide
bonds required for stabilization can complicate production and
range of application in both cases. Slightly larger scaffolds,
such as Fynomers (63 amino acids) (Grabulovski et al., 2007), af-
fitin (65 amino acids) (Mouratou et al., 2007), or sso7d (63 amino
acids) (Gera et al., 2011), have moved closer to the small size of
knottins and bicyclic peptides without the need for disulfides. Af-
fibodies (58 amino acids) are the smallest heavily investigated di-
sulfide-free scaffold in the literature (Lo¨fblom et al., 2010). Their
helical paratope has provided high affinity toward many targets;
however, they are typically severely destabilized after mutation
(midpoint of thermal denaturation [Tm] range, 37
C–65C;
median, 46C) (Hackel, 2014). There is still space to develop a
scaffold that approaches the small size of knottins and peptides
but also possesses the other beneficial properties.
We hypothesized that a thorough exploration of known protein
topologies could reveal an effective scaffold that pushed current
limits of small size with potential for high affinity and retention of
stability. A search of the PDB was performed to identify a small
protein with characteristics amenable to use as a protein scaf-
fold, including retention of stability upon mutation, lack of disul-
fides, and large available binding surface. Gene 2 protein from T7
phage was selected as the scaffold to investigate further, based
on the considered characteristics. A library of truncated gene 2
protein (Gp2) mutants was created by diversifying two solvent-
exposed loops in the protein. Using yeast surface display and af-
finity maturation, target-specific Gp2 molecules with nanomolar
or better affinity to three model proteins were isolated. The
binding proteins retained the wild-type secondary structure
characteristics and remained folded up to an average 72C.
These results verified Gp2 as a promising scaffold for the isola-
tion of strong, specific binders to a wide variety of targets and
motivated ligand discovery for the cancer biomarker epidermal
growth factor receptor (EGFR). EGFR is a clinical biomarker for
imaging and therapy due to its overexpression in multiple cancer
types, including head and neck, breast, bladder, prostate, kid-
ney, colorectal, non-small cell lung cancer, and glioma carci-
noma (Corcoran and Hanson, 2013; Hynes and MacDonald,
2009). Improved EGFR targeting could empower molecular im-
aging for patient stratification (Laurent-Puig et al., 2009; Moroni
et al., 2005; Scartozzi et al., 2009) and treatment monitoring as
well as advanced therapeutics. An EGFR-binding Gp2 was iso-
lated and matured. Binding was verified for membrane-bound
EGFR on mammalian cells, and Gp2 was used to detect relative
EGFR expression levels across multiple cell lines. The unique
combination of small size and efficient evolution of high affinity
and stability give Gp2 significant potential for the development
of molecular targeting agents.
RESULTS
Scaffold Discovery and Library Construction
The structural information in the PDBwas surveyed to locate po-
tential binding scaffolds. Based on the efficacy of diversifying
loops at one end of a b sandwich in antibody domains and theChemistry & Biology 22,type III fibronectin domain, we sought scaffolds with solvent-
exposed loops on a b-sheet-rich framework. As two loops can
provide sufficient diversity for high-affinity binding while a single
loop is often insufficient (Lipovsek et al., 2007), we sought protein
topologies with two adjacent loops amenable to mutation. All
proteins in the PDB were filtered to identify single domains of
40–65 amino acids and at least 30% b-sheet content, although
the PDB filter also anomalously returned several proteins as
large as 70 amino acids and with only 25% b-sheet content.
Resultant proteins were visualized in PyMol. Those with two
adjoining loops (regions of at least four amino acids without
defined secondary structure) and no disulfide bonds were re-
tained. The potential of the diversified loops to provide sufficient
binding interface while maintaining a folded protein was as-
sessed via two metrics: (1) solvent-accessible surface area of
the loop amino acids was calculated using serine as the side-
chain basis for all diversified sites to avoid wild-type sequence
bias; and (2) the average destabilization upon random mutation
of the loops was computed using Eris (Yin et al., 2007). Multiple
proteins exhibited favorable properties within several categories
(Figure 1). One scaffold that performed well on all criteria, espe-
cially differentiated by loop orientation, surface area (709 A˚2,
second highest), and stability (DDGf,mut = 5.6 kcal/mol, third
lowest), was selected for focused investigation: T7 phage gene
2 protein (Ca´mara et al., 2010).
T7 phage gene 2 protein, an E. coli RNA polymerase inhibitor
from T7 phage with 64 amino acids, was the top protein selected
by the ranking system (Figure 2). The coils at the N and C termini
(14 and 5 amino acids, respectively) were genetically removed
to minimize protein size. In addition, a framework mutation
(I17V) wasmadeon the basis of 59% frequency in naturally occur-
ring homologs and computational stabilization (DDGf,I/V =
3.8 kcal/mol via Eris; Yin et al., 2007). These modifications
resulted in the 5.2-kDa, 45-amino-acid Gp2 scaffold.
To evaluate the potential of Gp2 as a protein scaffold for mo-
lecular recognition, a combinatorial library of selectively random-
ized Gp2 sequences was constructed for use in discovery and
directed evolution. Two loops, comprising amino acids E7-S12
and V34-E39 (Figure 2), were selected as the proposed binding
surface, based on their lack of defined secondary structure,
continuous solvent-exposed face, and high solvent-exposed
surface area (709 A˚2). A yeast surface displayed library, contain-
ing approximately 4 3 108 Gp2 molecules based on the number
of yeast transformants, was constructed by randomizing six
amino acids from each loop using amino acid frequencies
consistent with antibody complementarity-determining regions
(CDRs) (Hackel et al., 2010), and allowing loop length diversity
of six, seven, or eight amino acids in each loop (Figure 2). Hem-
agglutinin (HA) and c-MYC epitope tags placed upstream and
downstream of the Gp2 gene, respectively, allowed for differen-
tiation through flow cytometry of yeast that lost the plasmid
(HA/c-MYC), yeast carrying a plasmid with incomplete Gp2
(HA+/c-MYC), and yeast expressing full-length Gp2 (HA+/
c-MYC+). A quality control check by flow cytometry indicated
that 44% of yeast harboring plasmid expressed full-length
Gp2. This was supported through sequencingGp2 genes, result-
ing in four full-length Gp2 genes, one Gp2 containing stop codon
in the diversified loop and five frameshifted genes. Therefore, the
actual size of the library was 1.8 3 108 unique, full-length Gp2946–956, July 23, 2015 ª2015 Elsevier Ltd All rights reserved 947
Figure 1. Summary of Information for Top Potential Scaffolds
(A) Structure and proposed paratope surface (red) of top five scoring scaffolds. Images created in PyMol.
(B) PDB ID, amino acid length, % b strand, and % a helix are all from the PDB. Loop residues are identified as residues between secondary structural elements.
Loop accessible surface area (ASA) is calculated using GetArea after mutating loop residues to serines within PyMol. DDGf,mut was calculated for random loop
mutants using Eris. Fibronectin (1ttg) and Affibody (2b88) are included for comparison. See also Table S1 for commonly used scaffolds.proteins. Amino acid diversity matched the designed distribution
(median absolute deviation, 0.5%; Figure S1).
Yeast Surface Display Selection against Model Protein
Targets
Lysozyme and immunoglobulin G (IgG) from rabbit and goat
were chosen as the first targets for evaluating the binding poten-
tial of the Gp2 scaffold. The differing size and surface topologies
of lysozyme (14 kDa) and the IgG proteins (150 kDa) test the
ability of the scaffold to target diverse proteins (Diamond,948 Chemistry & Biology 22, 946–956, July 23, 2015 ª2015 Elsevier L1974; Harris et al., 1998). The similarity of the two IgG proteins
test the ability of Gp2 to create very specific ligands, i.e. binding
to goat IgG but not rabbit IgG and vice versa.
During each evolutionary round, the Gp2 library underwent
two sorts to enrich specific binders (either with target-coated
magnetic beads or through fluorescence-activated cell sorting
[FACS]) and one c-MYC+ sort to isolate full-length Gp2. Sorted
Gp2 sequences were mutated through parallel error-prone
PCR reactions targeting the loops or the entire gene and trans-
formed into yeast with loop shuffling driven by homologoustd All rights reserved
Figure 2. Solution Structure of Gp2
Diversified amino acids are highlighted in red and underlined in sequence. The
N- and C-terminal tails removed to create the Gp2 scaffold are highlighted in
blue. An I17V (boldface in sequence) mutation was added based on preva-
lence in homologous protein sequences. Images created in Macpymol (PDB:
2WNM).recombination (Hackel et al., 2010). After a single maturation
cycle, clear binding was evident by flow cytometry for each
target campaign (data not shown). Two to four rounds of selec-
tion and mutation were carried out for each target to isolate
binders with low-nanomolar to picomolar affinity.
Single clones were isolated at the end of rounds where strong
binding was detectable by FACS. Target affinity on the surface
of yeast was determined by concentration titration (Table 1;
Figure 3A). Affinities measured on the surface of yeast have
been previously shown to match affinities measured by surface
plasmon resonance and related techniques (Gai and Wittrup,
2007). The goat IgG-binding population contained one dominant
sequence family that had affinities as strong as 200 ± 100 pM af-
ter one mutagenic cycle. The rabbit IgG-binding population con-
tained a family of low-nanomolar affinity binders at the end of the
third mutagenic cycle, which improved to 2.3 ± 1.4 nM after
another round of affinity maturation. A single dominant clone
group was isolated for lysozyme binders after the second round
of mutagenesis, albeit with weaker binding. Lysozyme-binding
clones isolated in subsequent rounds showed point mutationsTable 1. Characterization of Wild-Type Gp2 and the Top Binding M
Name Loop 1 Loop 2 Framew
Wild-type ESSEHS VPAGFE –
GaGIgG2.2.1 YDYDADYY YSNHSDYL E30V, Q
GaLysA0.3.3 FSYGNL SGAYEY –
GaRIgG3.2.3 HSVHGY GNALGY E30F, W
Loop 1 and Loop 2 indicate amino acid sequences in the diversified loops (E
resulting from error-prone PCR during evolution.KD values represent equilib
as purified soluble protein (±SD for nR 3). Tm indicates the midpoint of the
data not determined.
Chemistry & Biology 22,but no significant increase in binding affinity. A sublibrary was
created in which amino acid diversity was chosen based on
weighted scores of parental binding sequences, computational
stability analysis (using FoldX), natural homolog sequences,
and potential for complementarity (Figure S2). The strongest li-
brary member isolated was GaLysA0.3.3 with an affinity of 0.9 ±
0.7 nM (Figure 3A). During selection and maturation, the lyso-
zyme target was always displayed as a complex with streptavi-
din. Resultantly, GaLysA0.3.3 bound to a streptavidin-lysozyme
complex but not streptavidin or lysozyme alone. Nevertheless,
this still supports Gp2 as able to generate specific, high-affinity
binders to the target presented.
To examine target specificity, the strongest binding ligand
from each target campaign was incubated with four proteins at
1 mM. All Gp2 proteins show strong binding to the target protein
for which they were selected and matured, while showing fluo-
rescence only slightly above background signal for the three
other proteins (Figure 3B). Four depletion sorts were performed
per round, consisting of two sorts to bare streptavidin-coated
beads and two sorts to non-target protein-coated beads. This
sorting process enabled only Gp2 binders to the protein of inter-
est to be carried through the affinity maturation process.
Soluble Protein Characterization
To examine whether untethered Gp2 will retain its useful proper-
ties, the protein was produced and tested for binding and stabil-
ity. Wild-type Gp2 could not be produced at detectable levels in
a typical production E. coli strain, likely due to the native RNA po-
lymerase inhibition function of the protein (Nechaev and Severi-
nov, 1999). However, mutated clones were able to be produced,
presumably due to mutation of many of the residues on Gp2 nor-
mally required to interact with DNA during transcription inhibition
(Ca´mara et al., 2010). Protein titer, with no optimization, varied
between 0.2 and 2.2 mg/l for different Gp2 mutants. The JE1
E. coli strain has the b-jaw portion of the E. coli RNA polymerase
protein deleted (Ederth et al., 2002), and enabled production of
wild-type Gp2 at 0.7 mg/l. All Gp2 molecules were verified by
mass spectrometry to within 0.1% of the expected mass.
Structure and stability after mutation are important qualities of
a potential protein scaffold. To evaluate secondary structure
changes after Gp2was evolved for new binding function, circular
dichroism measurements were taken of the top binder for each
target. The ellipticity spectra of the binding Gp2 proteins deviate
only slightly from those of wild-type Gp2, suggesting that
the secondary structure remains relatively unchanged after mul-
tiple mutations in the backbone and entirely new loop regionsolecule for Each Target
ork KD,yeast (nM) KD,soluble (nM) Tm (
C)
– – 67 ± 1
32R 0.2 ± 0.1 0.4 ± 0.3 70 ± 4
0.9 ± 0.7 ND 65 ± 3
31G 2.3 ± 1.4 1.0 ± 0.5 80 ± 1
7-S12 and V34-E39). Framework indicates mutations outside of the loops
rium dissociation constants for clones displayed on the surface of yeast or
rmal denaturation as measured by circular dichroism (±SD for n = 2). ND,
946–956, July 23, 2015 ª2015 Elsevier Ltd All rights reserved 949
Figure 3. Binding Characterization
(A) Yeast displaying GaGIgG2.2.1 (red circles),
GaRIgG3.2.3 (green triangles), and GaLysA0.3.3
(gray squares) were incubated with the indicated
concentrations of biotinylated target. Binding was
detected by streptavidin-fluorophore via flow cy-
tometry. Titration indicates equilibrium dissocia-
tion constants of 0.2 ± 0.1, 2.3 ± 1.4, and 0.9 ±
0.7 nM.
(B) Yeasts were incubated with 1 mM goat IgG (G),
lysozyme (L), rabbit IgG (R), or transferrin (T).
Binding was detected by streptavidin-fluorophore
via flow cytometry. Data are normalized to signal
of intended target for each yeast strain. Error bars
represent ±SD of n = 3 samples. See Figure S3 for
full collection of affinity titration curves.(Figure 4A). The midpoint of thermal denaturation of each protein
was measured by monitoring the loss of secondary structure at
218 nm as temperature increased (Table 1; Figure 4B). Interest-
ingly, the average stability of Gp2 binding mutants increased by
5C over wild-type Gp2, which had a Tm = 67C ± 1C. Gp2
mutants raised to 98C and brought down to room temperature
had circular dichroism spectra similar to the initial measure-
ments (Figure 4A). GaGIgG2.2.1 (containing a framework muta-
tion, R44E, to increase production) maintained binding activity
(Figure 4D) after reverse-phase high-performance liquid chro-
matography (HPLC) and heating to 98C, illustrating the chemi-
cal and thermal stability of the protein.
The binding affinities of select soluble Gp2 clones, measured
by equilibrium competition titration, were 0.4 ± 0.3 nM for Ga
GIgG2.2.1 and 1.0 ± 0.5 nM for GaRIgG3.2.3 (Table 1; Figure 4C),
showing good agreement with the KDs obtained from yeast sur-
face display affinity titration.
EGFR-Targeting Gp2 Domains
The success and ease of ligand discovery for the three model
targets from the current Gp2 library motivated the search for a
Gp2 ligand that strongly and specifically bound EGFR for use
in cancer imaging or treatment. Through methods similar to
model targeting, Gp2 ligand discovery was performed using
soluble biotinylated EGFR ectodomain as the target. After the
second round of affinity maturation, strong binding was evident
by flow cytometry with 50 nM soluble EGFR (Figure 5A). Deep
sequencing indicated that GaEGFR2.2.3 was the dominant clone
in the library, and revealed several other families of sequences
that were enriched during evolution. Purified Gp2-EGFR2.2.3
binds to intact membrane-bound EGFR with an affinity of 18 ±
8 nM as measured by labeling A431 epidermoid carcinoma cells
(Figure 5B) that highly overexpress EGFR on their surface
(Hackel et al., 2012; Spangler et al., 2010). Gp2-EGFR2.2.3 ex-
hibits secondary structure consistent with the wild-type Gp2
domain (Figure 4C) and is thermally stable (Tm = 71
C ± 2C, Fig-
ure 5C). Fluorescence microscopy was used to evaluate binding
specificity. GaEGFR2.2.3, but not wild-type Gp2, effectively la-
bels the cell surface of EGFRhigh A431 epidermoid carcinoma
cells but not EGFRlow MCF7 mammary carcinoma cells
(Figure 5D). Moreover, binding of biotinylated GaEGFR2.2.3
was blockable by excess unlabeled Gp2 (Figure 5E). Gp2950 Chemistry & Biology 22, 946–956, July 23, 2015 ª2015 Elsevier Lbiotinylation was straightforward (with N-hydroxy succinimide
biotin) due to the lone lysine residue at the N terminus. To further
validate that the evolved Gp2 domain can differentiate between
different EGFR levels, four cell lines, A431 epidermoid carcinoma
(EGFRhigh), MDA-MB-231 mammary carcinoma (EGFRmid),
DU145 prostate carcinoma (EGFRmid), and MCF7 mammary
carcinoma (EGFRlow), were labeled with GaEGFR2.2.3 and a sec-
ondary fluorophore. Fluorescence signal correlated with the cell
surface expression level of EGFR (Figure 5F).
Deep Sequencing of Naive and Binding Populations
Deep sequencing was performed on the original library and the
first enriched population in each target campaign that displayed
significant selective binding represented by a 10:1 ratio of cells
on target beads to control beads. Multiple binding sequence
families were identified for each target (4,209 unique sequences
in 153 families identified by 85% sequence identity). Site-wise
changes in amino acid frequencies, relative to the original library,
for heavily diversified loops (Figure 6A) and framework sites
subject to error-prone PCR (Figure 6B) reveal site-specific amino
acid preferences. In addition, loop length frequency shows
a slight change from the initial library to the evolved binders
(Figure 6C).
DISCUSSION
We sought to identify a protein scaffold with a unique combina-
tion of small size and robust evolvability of specific, high-affinity
binding while retaining stability, and sought to evaluate the
ability to identify such a scaffold via systematic analysis of pro-
tein topology and an estimation of mutational tolerance. Gp2
provides very small size (5 kDa, 45 amino acids) and has been
efficiently evolved, to four different targets, to picomolar to
nanomolar affinities with good specificity including strong
discrimination between related IgGs. Evolved molecules exhibit
good thermal and chemical stability (Tm = 65
C–80C with
reversible unfolding and tolerance to reverse-phase chromatog-
raphy) and are functional in cellular assays. Gp2 succeeded with
the combination of an effective topology, diversification design
(tolerant loops of sufficient size, antibody-inspired amino acid
bias, and shape diversity via loop length variation), and evolu-
tion method.td All rights reserved
Figure 4. Soluble Gp2 Characterization
(A and B) Purified Gp2 clones (blue, wild-type; red, GaGIgG2.2.1; green, GaRIgG3.2.3) were analyzed by circular dichroism spectroscopy. (A) Molar ellipticity (q)
was measured at indicated wavelengths before (solid lines) and after (dashed lines) thermal denaturation. (B) Molar ellipticity was monitored at 218 nm upon
heating from 25C to 98C at 1C per minute.
(C) Biotinylated IgG (2 nM goat or 4 nM rabbit as appropriate) was incubated with the indicated concentration of purified Gp2 and used to label yeast displaying
the corresponding Gp2 clone. IgG binding was measured by streptavidin-fluorophore via flow cytometry.
(D) Purified GaGIgG2.2.1 was subjected to various treatments prior to use in the competitive binding assay (as in C). Unblocked is a control without Gp2
competition. Pre-HPLC uses competition by GaGIgG2.2.1 that was purified on a metal affinity column. Post-HPLC uses competition by GaGIgG2.2.1 purified by
metal affinity chromatography and reverse-phase high-performance liquid chromatography and lyophilization. Post-heat uses competition by GaGIgG2.2.1
purified as in Post-HPLC along with heating to 98C and cooling back to 22C. Error bars are ±SD on n = 2 samples. See Figure S2 for GaLysA0.3.3.The particular topology of an a helix opposite a three-strand b
sheet underpinning two diversified loops is a new structure for a
generalized binding scaffold. Of course, loops have been suc-
cessful with numerous other topologies including—as examples
rather than an all-inclusive list—antibodies, fibronectin domains,
and GFP (Pavoor et al., 2009). Yet not all loop-presenting frame-
works are equally efficacious, as evidenced by the varying per-
formance of different scaffolds (Binz et al., 2005). Of note here,
the second candidate in our theoretical scaffold evaluation,
an SH3 domain from CD2 associated protein (Roldan et al.,
2011), has substantially different framework topology and loop
orientation (Figure 1). This SH3 domain is a homolog (root-
mean-square deviation = 1.4 A˚ and TM score = 0.79, where >0.5
indicates similar fold; Zhang and Skolnick, 2005) of the Fynomer
scaffold, which has been evolved for low-nanomolar affinity to
five targets (Table S1) (Grabulovski et al., 2007; Panni et al.,
2002). While the scaffold evaluation algorithm provides a frame-
work for comparison, comparative experimental evaluation of
numerous scaffolds is beyond the scope of the current study.
Importantly, the demonstrated efficacy of Gp2 provides evi-
dence of an improved ability to merge design goals in evolu-
tionary capacity, affinity, and stability if the topology is properly
selected.
Regarding evolutionary library design, while the diversified
loops provided sufficient diversity for high-affinity binding, adja-
cent frameworkmutations in several cloneswere noted (Table 1).
Deep sequencing suggests that added diversity at the N-termi-
nal edge of the second loop could be beneficial, as E30, W31,
and Q32 exhibited higher than average variance in binders rela-
tive to the naive library (p < 0.001), presumably resulting from
error-prone PCR during evolution (Figure 6B). In addition, K1
also exhibits an increased mutation rate (p = 0.006), perhaps to
account for change in exposure or structure due to the removal
of the N-terminal tail. Conversely, lower than average mutation
rates of sites F2, A4, P16, A25, Y33, and V40 (p < 0.001) suggestChemistry & Biology 22,an evolutionary benefit to conservation at those sites. Notably,
Y33 and V40 directly flank the diversified region of the second
loop and are relatively buried in the protein core (19% and
21% solvent accessibility, respectively), suggesting a loop-
anchoring benefit. Overall, mutation tolerance correlated with
solvent accessibility (p = 0.001, Figure S1). Antibody-inspired
amino acid distributionwas effective as it was closelymaintained
in binding sequences (Figure 6A), although evolutionary effi-
ciency would benefit from slightly increased glycine, especially
at select sites: amino acids 9–11 in the middle of the first loop
and 34–35 at the start of the second loop. Meanwhile, evolu-
tionary preference was evident for hydrophilic residues at sites
10 and 36 and hydrophobic residues at sites 12, 37, and 38.
Loop length diversity was effectively utilized in binding se-
quences with a slight trend toward a longer first loop (18%
decrease of wild-type 6-amino-acid length and 33% increase
of 8-amino-acid loop; p < 0.001) and a second loop of wild-
type length (12% increase; p < 0.001) (Figure 6C). Collectively,
the diversification design was effective yet represents an avenue
for improvement. While the Gp2 scaffold was robust in efficiently
identifying effective bindingmolecules for each of the four dispa-
rate targets, one possible limitation is themodest number of lead
molecules for each target. As scaffold size is reduced, the need
to simultaneously optimize inter- and intramolecular interactions
is heightened, and the solution space is diminished. While all
evolved clones exhibited appropriate secondary structure,
good thermal stability, and effective binding, the frequency of
mutational tolerance of the naive library could be different. In
fact, evolved proteins were readily produced in E. coli, albeit at
moderate yields, and eight randomly selected initial library mu-
tants were unable to be recovered in detectable amounts (data
not shown), suggesting lack of solubility or stability in some naive
mutants. Refining the combinatorial library using site-wise opti-
mization of diversity based on the aforementioned data could
improve the breadth of solutions.946–956, July 23, 2015 ª2015 Elsevier Ltd All rights reserved 951
Figure 5. GaEGFR2.2.3 Affinity and Stability
(A) Population of yeast displaying Gp2 incubated with 50 nM EGFR and anti-c-MYC antibody. Secondary fluorophores detect binding of EGFR and antibody.
Spread of double-positive cells suggests moderate diversity of EGFR-binding Gp2 molecules. GaEGFR2.2.3 was collected from top 1% of double positives.
(B) A431 cells were incubated with indicated amount of purified Gp2. Binding was detected by anti-His6 fluorophore. Titration indicates an equilibrium disso-
ciation constant of 18 ± 8 nM.
(C) Molar ellipticity was monitored at 218 nm upon heating from 25C to 98C at 1C per minute. Molar ellipticity before (solid) and after (dashed) thermal
denaturation is inset.
(D) Fluorescence microscopy of adhered cancer cell lines, incubated with 100 nM Gp2 protein and detected by anti-His6-fluorescein. A431 cells labeled with
GaEGFR2.2.3 (left column) show localization to cell surface. A431 cells labeled with Gp2 WT (middle column) and MCF7 cells labeled with GaEGFR2.2.3 (right
column) show very little detectable binding. Scale bar represents 200 mm.
(E) A431 cells preincubated with PBS or 1 mM GaEGFR2.2.3 and labeled with 200 nM biotinylated GaEGFR2.2.3. Binding detected with streptavidin-fluorophore.
(F) Cancer cell lines expressing varying levels of EGFR: MCF7with 23 104 receptors (gray line) (Reilly et al., 2000), MDA-MB-231 with 13 105 receptors (red dots)
(Reilly et al., 2000), DU145 with 2 3 105 receptors (black dashes) (Malmberg et al., 2011), and A431with 3 3 106 (green dashes) (Spangler et al., 2010) were
incubated with 1 mM GaEGFR2.2.3 and detected with anti-His6-fluorescein by flow cytometry.Effective lead ligands, such as GaEGFR2.2.3, which binds
cellular EGFR with 18 ± 8 nM affinity and has high thermal stabil-
ity (71C), were identified. GaEGFR2.2.3 was effective in cellular
labeling for immunofluorescence, flow cytometry, and binding
inhibition. Notably, GaEGFR2.2.3 contains a single lysine at the
N terminus, distal to the proposed binding paratope, for conjuga-
tion of imagingmoieties or molecules of therapeutic interest. The
conjugation of biotin to the molecule without strong inhibition of
binding suggests that other molecules can similarly be conju-
gated. Similar small proteins have shown advantages over anti-
bodies in molecular imaging of solid tumors (Natarajan et al.,
2013; Orlova et al., 2009), for which enhanced transport and
clearance afforded by small size are particularly valuable, and
have exhibited clinical potential (Baum et al., 2010). It should
be noted that, as with any synthetically engineered protein with
non-human sequence components, immunogenicity of evolved952 Chemistry & Biology 22, 946–956, July 23, 2015 ª2015 Elsevier Lmolecules will need to be evaluated. Overall, Gp2 molecules
represent a promising alternative with a unique blend of small
size and robust evolution of stable, high-affinity binders.
SIGNIFICANCE
A systematic evaluation of the PDB based on size, protein
secondary structure, paratope structure, and resilience to
mutation led to further investigation of the small Gp2
domain. The ability to discover and evolve novel binding
function on mutated Gp2 molecules is generalizable, with
four targets currently tested. The small size, retention of
thermal stability, and ease of evolving high-affinity binding
provide a unique and powerful combination in an alternative
scaffold. The Gp2 molecules reported here that bind
strongly and specifically to rabbit IgG, goat IgG, lysozyme,td All rights reserved
Figure 6. Deep Sequencing Comparison of Naive and Binding Populations
All sequences were grouped into families and damped.
(A) Diversified loop positions (CDR0) are shown at the top, with 9a and 9b, or 36a and 36b, representing loop length diversity positions. Positions with an absolute
change of 5% or greater are labeled. All labeled positions have p < 0.001 (nR 96, number of damped sequences).
(B) Relative change in amino acid frequency by framework position from the naive library to combined mature populations. Certain mutations are more common
than others due to error-prone PCR limitations. Positions where wild-type was conserved (#) or mutated (*) significantly more often (p < 0.001 for 3% deviation, n
R 421) than the mean mutation rate are denoted.
(C) Frequency of Gp2 loop length in amino acids. The naive library was designed with equal loop length frequencies, but DNA bias during construction lead to
overrepresentation of shorter loops. Mature combines high throughput sequencing from the four binding populations. All have p < 0.001. Error bars are ±SD for
n = 4.9 3 104 for naive and nR 477 for mature (number of damped sequences). See also Figure S1.and EGFR have immediate use in biotechnology or, in the
case of GaEGFR2.2.3, as a potential clinical imaging agent,
due to their single distal lysine available for conjugation
of small molecules or other moieties. Moreover, deep
sequencing of the binding populations provided insights
on Gp2 evolution including mutational tolerance at non-
loop positions and amino acid preference at individual
loop positions. Overall, the initial successes of Gp2 com-
bined with knowledge gained from sequence analysis sug-
gest a promising scaffold that can be used to discover small,
stable binders to many targets while providing an opportu-Chemistry & Biology 22,nity for ongoing study of evolutionary optimization of inter-
and intramolecular interactions in a small scaffold.
EXPERIMENTAL PROCEDURES
Detailed experimental procedures are described in Supplemental Experi-
mental Procedures.
PDB Analysis
All single domains within the PDB (accessed November 2011) were filtered to
identify those with a size of 40–65 amino acids and at least 30% b sheet. Note
that several proteins outside of these bounds were nevertheless returned by946–956, July 23, 2015 ª2015 Elsevier Ltd All rights reserved 953
the website’s filter. PyMol (Schro¨dinger) was used to visualize the structures of
the 259 remaining proteins, and those that contained two or more adjacent sol-
vent-exposed loopswhosesurfaces formedonecontinuous faceandhadnodi-
sulfide bonds were further considered. The solvent-accessible surface area of
the loop residues was calculated, using a 1.4-A˚ sphere, after mutating residues
to serines in PyMol (Fraczkiewicz and Braun, 1998). For the top 14 proteins, the
destabilization upon random mutation of the loop residues was calculated
using Eris (Yin et al., 2007). Amino acid sequences were randomly generated
using equal probability of each amino acid within the loops noted in Figure 1.
Randommutantswereanalyzeduntil themeandestabilizationconvergedwithin
0.25kcal/mol for at least tenconsecutivemutants (minimum35mutants in total).
This resulted in a maximum of 84 mutants with a median of 42 mutants.
Library Construction
A genetic library was constructed based on a truncated form of T7 phage gene
2 protein, the top scoring protein, in which the sequence encoding for two
loops was randomized using degenerate oligonucleotides encoding for an
amino acid distribution mimicking antibody CDRs (Hackel et al., 2010). At
diversified positions (Figure 1) the mixtures of nucleotides were 15% A and
C, 25% G, and 45% T in the first position; 45% A, 15% C, 25% G, and 15%
T in the second position; and 45% C, 10% G, and 45% T in the third position.
The DNA was transformed into yeast surface display system strain EBY100 via
homologous recombination with a pCT vector (Chao et al., 2006). The total
number of transformants was determined through serial dilution on SD-CAA
plates (0.07 M sodium citrate [pH 5.3], 6.7 g/l yeast nitrogen base, 5 g/l casa-
mino acids, and 20 g/l glucose). Flow cytometry was used to determine the
amount of full-length Gp2 displayed, through labeling of the N-terminal HA
epitope and C-terminal c-MYC epitope, and supported with DNA sequence
verification. The design of the focused lysozyme library is described in Supple-
mental Experimental Procedures.
Binder Selection and Affinity Maturation
Yeasts displaying the Gp2 library were exposed to control magnetic beads
(first avidin-coated beads, then beads with immobilized non-target protein)
to remove any non-specific binding interactions. Yeasts were then exposed
to magnetic beads with immobilized biotinylated target protein (goat IgG, rab-
bit IgG, lysozyme, or EGFR ectodomain) and bound yeasts were selected.
Magnetic sorts on the initial library were performed at 4C and only one
wash. Non-naive populations were sorted more stringently, at room tempera-
ture and with three washes. Flow cytometry selections, with biotinylated target
protein and Alexa Fluor 647-conjugated streptavidin, were used (Hackel and
Wittrup, 2010) to isolate full-length (c-MYC positive) Gp2 domain mutants
that bind selectively and with high affinity toward the target proteins. Loop-
focused and total gene error-prone PCR, using nucleotide analogs, and ge-
netic loop shuffling between binding sequences were used to evolve improved
function (Hackel et al., 2008).
Illumina MiSeq Analysis
Illumina MiSeq paired-end sequencing was conducted to obtain 4.9 3 104
reads from the naive library and a total of 6.4 3 105 (coefficient of variation =
24%) reads from binding populations. Loop 1 was analyzed independently
from loop 2. Mature loop-1 sequences were grouped into 95 families (>60%
sequence similarity) with 249 unique sequences, and after damping (quad
rooted) the adjusted sequence count was n R 173 at each position. Mature
loop-2 sequences were grouped into 96 families with 198 unique sequences,
and after damping the adjusted sequence count was nR 96 at each position.
Sequences from the naive library population were grouped into 4.93 104 fam-
ilies with 4.9 3 104 unique sequences, and after damping the adjusted
sequence count was R1.1 3 104 (due to fewer sequences at extended loop
positions). Mature framework analysis grouped the sequences into 153 fam-
ilies (>85% sequence similarity) with 4,209 unique sequences, and after damp-
ing the adjusted sequence count was nR 421 at each position. p values were
calculated using a Welch t test while assuming a normal distribution and using
the number of damped sequences at each position as the sample size.
Affinity and Biophysical Properties
Binding affinities of evolved Gp2 molecules were determined by titrating target
and evaluating binding using yeast surface display and flow cytometry (Chao954 Chemistry & Biology 22, 946–956, July 23, 2015 ª2015 Elsevier Let al., 2006). ForGaLysA0.3.3AlexaFluor488-conjugatedstreptavidinwasmixed
equimolarly with singly biotinylated lysozyme at 2 mMprior to titration and yeast
labeling. Gp2 domains were produced in E. coli, using strain JE1(DE3) for wild-
type or BL21(DE3) for other Gp2 domains, purified bymetal affinity chromatog-
raphy and reverse-phase HPLC, and verified by mass spectrometry. Purified
Gp2 was suspended at 0.2–0.9 mg/ml in PBS (8.0 g/l NaCl, 0.2 g/l KCl,
1.44 g/l Na2HPO4, 0.24 g/l KH2PO4 [pH 7.2]) or 10 mM sodium acetate
(pH5.5), and secondary structure and thermal stabilitywere evaluatedbywave-
length (200–260 nm) and temperature scans (25–98C at 218 nm) via circular
dichroism spectroscopy. Binding affinity was further measured by equilibrium
competition titration with purified Gp2, target protein, and Gp2 displayed on
the yeast surface using flow cytometry (Lipovsek et al., 2007). For cellular
EGFR affinity, A431 epidermoid carcinoma was cultured in DMEM with 10%
fetal bovine serum at 37C in humidified air with 5% CO2. Cells to be used in
flowcytometryweredetachedusing trypsin for a shorter time (3–5min) than rec-
ommended. Detached cells were washed and labeled with Gp2-EGFR2.2.3 at
varying concentrations for 15–30 min at 4C. Cells were pelleted and washed
with PBSA (PBS + 0.1% w/v BSA), then labeled with fluorescein-conjugated
rabbit anti-His6 antibody for 15min at 4
C. For blocking, cells were also labeled
with biotin-Gp2-EGFR2.2.3 and detected by Alexa Fluor 647-conjugated strep-
tavidin. Fluorescence was analyzed on a C6 Accuri flow cytometer (BD Biosci-
ences). The equilibrium dissociation constant, KD, was identified by minimizing
the sum of squared errors assuming a 1:1 binding interaction.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.chembiol.2015.06.012.
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